Avidity Biosciences Inc (RNA)

$5.94 0.44 (6.90%)

16:00 EDT RNA Stock Quote Delayed 30 Minutes

7 Unknown Biotech Stocks That Could Rocket in 2023

By Faisal Humayun, InvestorPlace Contributor Sep 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Volume:

Previous Close -

Market Cap 323.51M

PE Ratio -1.91

EPS -3.11

Volume (Avg. Vol.) 652,716

Day's Range $5.84 - $6.49

52-Week Range $5.84 - $25.74

Dividend & Yield N/A (N/A)

RNA Stock Predictions, Articles, and Avidity Biosciences Inc News

From the Web

Avidity Biosciences GAAP EPS of -$0.74 beats by $0.11, revenue of $2.23M beats by $0.48M (NASDAQ:RNA)

From Seeking Alpha May 9, 2023

Avidity Biosciences press release (NASDAQ:RNA): Q1 GAAP EPS of -$0.74 beats by $0.11.Revenue of $2.23M (+23.9% Y/Y) beats by $0.48M.

After Falling 18% in 1 Day, Is This Growth Stock Done For?

From The Motley Fool Apr 11, 2023

It's too soon to predict doom, but that doesn't mean things are good.

Avidity stock falls after muscle disorder trial concluded amid FDA hold

From Seeking Alpha Mar 30, 2023

Avidity Biosciences (RNA) stock fell after providing regulatory update on AOC 1001 for myotonic dystrophy type 1. Read more here

Avidity Biosciences GAAP EPS of -$88.00 misses by $87.11, revenue of $2.77M beats by $0.89M (NASDAQ:RNA)

From Seeking Alpha Feb 28, 2023

Avidity Biosciences press release (RNA): Q4 GAAP EPS of -$88.00 misses by $87.11.Revenue of $2.77M (+49.7% Y/Y) beats by $0.89M.Research and Development (R&D) Expenses: R&D...

Avidity's therapy for rare muscle disorder gets FDA fast track status

From Seeking Alpha Jan 18, 2023

The U.S. Food and Drug Administration ((FDA)) granted fast track designation to Avidity Biosciences' (RNA) AOC 1020 to treat facioscapulohumeral muscular dystrophy ((FSHD)).FSHD is...

Avidity Biosciences (RNA) Receives a Buy from SVB Securities

From TipRanks Nov 14, 2022

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Avidity Biosciences (RNA – Research Report) on November 9 and set a price target of $50.00. ...